All In Biotech

Drug Trial Radar · NCT00733811

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients

Last checked: Nov 20, 2026Latest source record: Aug 13, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Sep 2000

Primary completion

Jan 2008

Study completion Jan 2008

Sponsor

Lead sponsor
Azienda Ospedaliera V. CervelloAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 13 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using different schedules of treatment, in the majority of the 13 clinical trials published between 1990 and 2008.No statistically significant difference was shown between these two interventions during, at most, 18 months of treatment.Three randomised trials that compared sequential DFP-DFO treatment versus DFO alone reported controversial results but this could be due to small sample sizes and short treatment duration. In fact, no trial with treatment duration longer than 18 months15, which reported on mortality, adverse events, serum ferritin concentrations, as well as costs has so far been published. This long-term sequential DFP-DFO treatment versus DFP alone treatment trial was conducted to assess the impacts of these chelation treatments on serum ferritin concentrations, mortality, adverse events, and costs in thalassemia major patients.

Conditions

  • Beta-Thalassemia
  • Thalassemia Major

Interventions

  • Deferiprone (DFP) and Deferoxamine (DFO)Drug

    Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week

  • Deferiprone (DFP)Drug

    DFP alone at 75 mg/kg divided into three oral daily doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. difference between multiple observations of the serum ferritin concentrationsTime frame: five-year treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ao V. Cervello

    Palermo, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.